NCT00678288 - A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions

Carcinoma, Renal Cell

Interventions

DRUG

Sorafenib (Nexavar, BAY43-9006)

Sorafenib 400 mg (two 200 mg tablets) BID PO, continuously

DRUG

Sorafenib (Nexavar, BAY43-9006) + Interferon

Sorafenib 400 mg (two 200 mg tablets) BID PO, continuously. IFN alpha-2a 3MIU FIW s.c., from Monday to Friday (total weekly dose 15 MIU) s.c., to start one week after commencing sorafenib.

Trial Locations (35)

24

Dublin

1090

Vienna

5020

Salzburg

13015

Marseille

13385

Marseille

27100

Pavia

28041

Madrid

28046

Madrid

31008

Pamplona

31052

Toulouse

33000

Bordeaux

33006

Oviedo

33081

Aviano

37045

Legnago

42100

Reggio Emilia

44020

Nantes

46009

Valencia

51100

Reims

54000

Vandœuvre-lès-Nancy

64100

Bayonne

67000

Strasbourg

75014

Paris

75651

Paris

80131

Napoli

84000

Avignon

Unknown

Cork

06156

Perugia

80-219

Gdansk

20-090

Lublin

04-141

Warsaw

50 - 556

Wroclaw

08035

Barcelona

SW3 6JJ

London

HA6 2RN

Northwood

NE4 6BE

Newcastle upon Tyne